// App-Quantinova.ai

4398 : Final Results Of A Phase 2 Study Of Vorinostat Plus Rituximab In Newly Diagnosed, Relapsed Or Refractory Indolent Non-Hodgki-s Lymphoma

Researchers

Presenter

  • Robert Chen

Principal Investigators

  • Paul Frankel

  • Leslie Popplewell

  • Tanya Siddiqi

  • Wei Ye

  • Joel Conrad

  • Michelle Mott

  • Auayporn Nademanee

  • Myo Htut

  • Stephen J. Forman

  • Mark Kirschbaum

Medical Centers

  • Department of Hematology and Hematopietic Cell Transplantation, City of Hope, Duarte, CA

  • Hematology and HCT, City of Hope National Medical Center, Duarte, CA

  • Hematology, Penn State Hershey Cancer Institute, Hershey, PA

  • City of Hope National Medical Center, Duarte, CA

  • Hematology and HCT, City of Hope National Medical Center, Duarte, CA

  • Hematology/Stem Cell Transplantation, City of Hope, Duarte, CA

  • Department of Hematology and Hematopietic Cell Transplantation, City of Hope, Duarte, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Waldenstrom’s macroglobulinemia

  • Non-Hodgkin's Lymphoma

  • Pulmonary embolism

  • Hodgkin's Lymphoma

  • B-Cell Non-Hodgkin Lymphoma

  • Thrombocytopenia

  • Neutropenia

  • Lymphocytopenia

  • Non‐Hodgkin Lymphoma

  • Venous thrombosis

  • Lymphomas

Biomarkers

  • C-C Motif Chemokine Ligand 2

  • Cluster of Differentiation 25

  • C-X-C motif chemokine ligand 9

  • Epidermal growth factor

  • Interleukin 6

  • Interleukin-2

Drug/Treatment

  • Enoxaparin

  • Enoxaparin sodium

  • Vorinostat

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved